New anti-epileptic drug approved by European Commission | Pharmaceutics_R&D |

The first in a new class of treatment for uncontrolled partial onset of seizures, which is the most common form of epilepsy, has been approved for use in the UK by the European Commission (EC).
Fycompa (perampanel) is the first and only licensed anti-epileptic drug to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of epileptic seizures. It was discovered and developed by Eisai, in the UK and Japan. (...) -  by Hannah Blake, 13th September, Pharmaphorum